These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. The molecular signature of AML with increased ALDH activity suggests a stem cell origin. Blume R; Rempel E; Manta L; Saeed BR; Wang W; Raffel S; Ermakova O; Eckstein V; Benes V; Trumpp A; Ho AD; Lutz C Leuk Lymphoma; 2018 Sep; 59(9):2201-2210. PubMed ID: 29334844 [TBL] [Abstract][Full Text] [Related]
45. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595 [TBL] [Abstract][Full Text] [Related]
46. Inhibition of mitochondria induces apoptosis and reduces telomere length and activity in acute myeloid leukemia stem cells. Valipour B; Davari S; Farahzadi R; Pourrasol S; Mehran N; Dizaji Asl K; Altaha SM; Hojjati Z; Nozad Charoudeh H Cell Biochem Funct; 2023 Dec; 41(8):1477-1487. PubMed ID: 38014526 [TBL] [Abstract][Full Text] [Related]
47. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection. Al-Mawali A; Pinto AD; Al-Zadjali S Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396 [TBL] [Abstract][Full Text] [Related]
48. Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity. Arnone M; Konantz M; Hanns P; Paczulla Stanger AM; Bertels S; Godavarthy PS; Christopeit M; Lengerke C Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322769 [TBL] [Abstract][Full Text] [Related]
49. Tracing Leukemia Stem Cells and Their Influence on Clinical Course of Adult Acute Myeloid Leukemia. Kandeel EZ; El Sharkawy N; Hanafi M; Samra M; Kamel A Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):383-393. PubMed ID: 32201129 [TBL] [Abstract][Full Text] [Related]
50. DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax. Ye S; Xiong F; He X; Yuan Y; Li D; Ye D; Shi L; Lin Z; Zhao M; Feng S; Zhou B; Weng H; Hong L; Ye H; Gao S Theranostics; 2023; 13(1):77-94. PubMed ID: 36593968 [No Abstract] [Full Text] [Related]
51. Microfluidic chip with reversible interface for noninvasive remission status monitoring and prognosis prediction of acute myeloid leukemia. Lai Q; Song J; Zha J; Zheng H; Deng M; Liu Y; Lin W; Zhu Z; Zhang H; Xu B; Yang C Biosens Bioelectron; 2023 Jan; 219():114803. PubMed ID: 36252315 [TBL] [Abstract][Full Text] [Related]
52. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Nelde A; Schuster H; Heitmann JS; Bauer J; Maringer Y; Zwick M; Volkmer JP; Chen JY; Stanger AMP; Lehmann A; Appiah B; Märklin M; Rücker-Braun E; Salih HR; Roerden M; Schroeder SM; Häring MF; Schlosser A; Schetelig J; Schmitz M; Boerries M; Köhler N; Lengerke C; Majeti R; Weissman IL; Rammensee HG; Walz JS Blood Cancer Discov; 2023 Nov; 4(6):468-489. PubMed ID: 37847741 [TBL] [Abstract][Full Text] [Related]
53. The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia. Li Q; Wang M; Liu L Biochem Pharmacol; 2023 Jun; 212():115539. PubMed ID: 37024061 [TBL] [Abstract][Full Text] [Related]
54. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Ito S; Barrett AJ; Dutra A; Pak E; Miner S; Keyvanfar K; Hensel NF; Rezvani K; Muranski P; Liu P; Larochelle A; Melenhorst JJ Stem Cell Res; 2015 Jan; 14(1):95-104. PubMed ID: 25535865 [TBL] [Abstract][Full Text] [Related]
55. Prognostic Impact and Phenotype of Residual Acute Myeloid Leukemia Stem Cells. Jaddaoui S; Bencharef H; Lamchahab M; Quessar A; Oukkache B Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704721 [TBL] [Abstract][Full Text] [Related]
56. Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF). Maag AH; Swanton H; Kull M; Vegi NM; Feuring M Cytometry A; 2023 Jul; 103(7):551-562. PubMed ID: 36647792 [TBL] [Abstract][Full Text] [Related]
57. Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches. Thakral D; Gupta R; Khan A Stem Cell Rev Rep; 2022 Jun; 18(5):1756-1773. PubMed ID: 35412219 [TBL] [Abstract][Full Text] [Related]
58. Cancer stem cells in hematological disorders: current and possible new therapeutic approaches. Annaloro C; Onida F; Saporiti G; Lambertenghi Deliliers G Curr Pharm Biotechnol; 2011 Feb; 12(2):217-25. PubMed ID: 21044004 [TBL] [Abstract][Full Text] [Related]
59. [Progress in the studies of acute myelogenous leukemia stem cell]. Cui JW; Zhang XM; Wang GJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Oct; 11(5):549-52. PubMed ID: 14575558 [TBL] [Abstract][Full Text] [Related]
60. JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia. De Grandis M; Bardin F; Fauriat C; Zemmour C; El-Kaoutari A; Sergé A; Granjeaud S; Pouyet L; Montersino C; Chretien AS; Mozziconacci MJ; Castellano R; Bidaut G; Boher JM; Collette Y; Mancini SJC; Vey N; Aurrand-Lions M Cancer Res; 2017 Dec; 77(23):6627-6640. PubMed ID: 28972073 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]